Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa. 2005

Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
Laboratoire de Santé Hygiène Mobile, Yaoundé, Cameroon.

Recently T-20 or enfuvirtide, the first drug of a new class of antiretrovirals targeting the entry stage of the virus life cycle, has been clinically approved. Enfuvirtide is a peptide derived from the HR2 region of the transmembrane glycoprotein from the HXB2 HIV-1 subtype B prototype strain that binds to the HR1 region. Drug resistance seems to occur in the HR1 region between amino acids 36 and 45. We examined to what extent this region is conserved in 184 non-B strains from Cameroon: 132 (71.7%) CRF02-AG, 14 (7.6%) subtype A, 11 (5.9%) F2, 9 (4.8%) subtype D, 8 (4.3%) subtype G, 4 (2.1%) CRF01-AE, 4 (2.1%) CRF11-cpx, and 2 (1.1%) CRF06-cpx. Among the 184 strains studied, no amino acid mutation was found in the highly conserved three amino acid motif at codons 36-38 (GIV) that are important determinants of viral susceptibility to enfuvirtide. Other common substitutions like Q40H and N42T were also absent. The N42S polymorphism was present in 148 (80.4%) strains. Analysis of the HR2 domain, from which the peptide is derived, indicated a much greater genetic variability as compared to HR1.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011995 Recombination, Genetic Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. Genetic Recombination,Recombination,Genetic Recombinations,Recombinations,Recombinations, Genetic
D002163 Cameroon A republic in central Africa lying east of CHAD and the CENTRAL AFRICAN REPUBLIC and west of NIGERIA. The capital is Yaounde. Republic of Cameron,Cameroons,United Republic of Cameroon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077560 Enfuvirtide A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS. DP 178,DP-178,DP178,Fuzeon,Pentafuside,Peptide T20,T20 Peptide,T20, Peptide
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV

Related Publications

Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
June 2011, Journal of acquired immune deficiency syndromes (1999),
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
October 2002, AIDS research and human retroviruses,
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
January 2009, Journal of acquired immune deficiency syndromes (1999),
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
June 2003, Journal of acquired immune deficiency syndromes (1999),
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
February 1996, Lancet (London, England),
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
January 2014, PloS one,
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
August 1995, AIDS research and human retroviruses,
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
January 2004, AIDS research and human retroviruses,
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
July 1997, AIDS research and human retroviruses,
Avelin Fobang Aghokeng, and Léonard Ewane, and Bih Awazi, and Aubin Nanfack, and Eric Delaporte, and Léopold Zekeng, and Martine Peeters
October 2007, AIDS research and human retroviruses,
Copied contents to your clipboard!